Abstract
A 61-year-old woman with lung adenocarcinoma failed first-line treatment and was placed on immunotherapy with nivolumab. FDG-PET/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton. Seven weeks after starting nivolumab, FDG-PET/CT showed mild residual activity in thoracic nodes and otherwise complete response. After 15 weeks, enlarged and FDG-avid axillary lymphadenopathy and worsening supraclavicular lymphadenopathy developed. After 20 weeks, FDG-PET/CT demonstrated marked improvement of axillary and supraclavicular lymphadenopathy. This case demonstrates that later progression of disease can still respond to continuing immunotherapy, hypothetically because of dynamic adaptations in the tug-of-war between the immunotherapy-augmented immune system and tumor.
Original language | English (US) |
---|---|
Pages (from-to) | 114-116 |
Number of pages | 3 |
Journal | Clinical nuclear medicine |
Volume | 43 |
Issue number | 2 |
DOIs | |
State | Published - Feb 1 2018 |
Keywords
- PET/CT
- flourodeoxyglucose
- immunotherapy
- lung cancer
- nivolumab
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging